{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268698","form_type":"8-K","ticker":null,"cik":"0001531048","company_name":"Inari Medical, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.399551+00:00","generated_at":"2026-06-09T00:08:17.363664+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inari Medical to acquire LimFlow for $250M cash, plus up to $165M in milestones","bullets":["Upfront purchase price of $250M in cash; contingent payments up to $165M based on commercial and reimbursement milestones.","LimFlow's TADV system received FDA approval in Sept. 2023; targets no-option CLTI patients facing amputation.","Transaction expected to close in Q4 2023; financed with cash on hand and borrowings under expanded credit facility.","Credit facility amended: revolver increased from $40M to $75M; BSBY rate + 1.60%-2.10% margin for new loans.","Inari sees CLTI as a $1.5B annual U.S. opportunity; conservative estimate of 55,000 treatable patients per year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268698","json":"https://secwatch.observer/filing/0001193125-23-268698.json","markdown":"https://secwatch.observer/filing/0001193125-23-268698.md","text":"https://secwatch.observer/filing/0001193125-23-268698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/d561000d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:08:17.363664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d39fae52f6501a3c4b36d3dec0c24fb057c55d2","claim":"Inari Medical, Inc. amended revolving credit of from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amo with Bank of America, N.A. at BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that range.","evidence_excerpt":"The Amendment, among other things, (i) increases the amount available under the revolving credit facility from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amount of the borrowing base, (ii) provides that advances under the Amended Credit Agreement will bear interest at a rate per annum equal to the BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that ranges from 0.60% to 1.10% in the case of Base Rate loans and 1.60% to 2.10% in the case of BSBY Rate loans depending on average daily availability, in each case with a floor of 0%, (iii) increases the letter of credit subline from $10.0 million to $18.75 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amo"},{"label":"Counterparty","value":"Bank of America, N.A."},{"label":"Rate","value":"BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that range"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"5418e6591f2fe8156e281f68dc206b547ac4594a","claim":"Inari Medical, Inc. entered into Share Purchase Agreement with LimFlow S.A. valued at Initial purchase price of $250,000,000, plus contingent payments up to $165,000,000 (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023, Lombardi Sub, LLC, a Delaware limited liability company (the “ Purchaser ”) and an indirect wholly-owned subsidiary of Inari Medical, Inc. (the “ Company ”, “ we ” or “ us ”), the Company, as guarantor of Purchaser’s financial obligations, LimFlow S.A., a French limited liability company (société anonyme) (“ LimFlow ”), equity holders of LimFlow (the “ Sellers ”) and Shareholder Representative Services LLC, a Colorado limited liability company (the “ Seller Representative ”), entered into a Share Purchase Agreement (the “ Purchase Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"LimFlow S.A."},{"label":"Value","value":"Initial purchase price of $250,000,000, plus contingent payments up to $165,000,000"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"material_agreement"},{"claim_id":"b52e201653348e1e1df3d331fe5b35bbc5ea2c55","claim":"Inari Medical, Inc. amended Amendment to Loan, Guaranty and Security Agreement with Bank of America, N.A. and other lenders valued at Increased revolving credit facility from lesser of $40.0 million and borrowing base to lesser of $75 (effective 2023-11-01).","evidence_excerpt":"On November 1, 2023, the Company, Inari Medical International, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, Inari Medical Latin America, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, each of the lenders signatory thereto (the “ Lenders ”) and Bank of America, N.A. (as the agent for the Lenders, the “ Agent ”) entered into an amendment (the “ Amendment ”) to the Loan, Guaranty and Security Agreement, dated as of September 4, 2020","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Bank of America, N.A. and other lenders"},{"label":"Value","value":"Increased revolving credit facility from lesser of $40.0 million and borrowing base to lesser of $75"},{"label":"Effective","value":"2023-11-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}